Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ru Zhou

Showing results (331-340 of 334) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 334 results.
Journal of Medicinal Chemistry|October 3, 2003
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimeticsPeter S Dragovich, Thomas J Prins, Ru Zhou, et al.
Journal of Medicinal Chemistry|March 20, 2023
Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1Rebecca A Gallego, Louise Bernier, Hui Chen, et al.
Journal of Medicinal Chemistry|December 9, 2024
Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of CancerRebecca A Gallego, Sujin Cho-Schultz, Matthew Del Bel, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 34

Showing results (331-340 of 334) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 334 results.
Journal of Medicinal Chemistry|October 3, 2003
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimeticsPeter S Dragovich, Thomas J Prins, Ru Zhou, et al.
Journal of Medicinal Chemistry|March 20, 2023
Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1Rebecca A Gallego, Louise Bernier, Hui Chen, et al.
Journal of Medicinal Chemistry|December 9, 2024
Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of CancerRebecca A Gallego, Sujin Cho-Schultz, Matthew Del Bel, et al.
Journal of Medicinal Chemistry|January 13, 2016
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Sajiv K Nair, Brion W Murray, et al.
Pageof 34